Skip to main content
. Author manuscript; available in PMC: 2008 Feb 12.
Published in final edited form as: J Am Coll Cardiol. 2007 Jul 23;50(6):528–536. doi: 10.1016/j.jacc.2007.03.057

Figure 7. Effects of DOX on Myocardial Endocannabinoid Content and CB 1/2 Receptor Expression.

Figure 7

(A) Evidence of CB1 receptor protein expression in total lysate of DOX-treated mouse heart tissue homogenate by Western blot analysis. (B and D) Evidence of CB1 and CB2 receptor gene expression by semiquantitative reverse transcription-polymerase chain reaction (RT-PCR) from complementary deoxyribonucleic acid of both untreated and DOX-treated mouse heart samples (B) and cardiomyocytes (D). (C) Evidence of CB1 receptor and CB2 receptor gene expression in heart tissue by quantitative real-time PCR after normalization to beta-actin (n = 6 to 15). (E) Effect of DOX on anandamide (AEA) and 2-arachidonylglycerol (2-AG) production in vivo by liquid chromatography mass spectrometry (LCMS) analysis of heart tissue samples. *p < 0.05 versus vehicle (n = 6). (F) Effect of DOX (1 μM for 2 h) on AEA and 2-AG production in vitro by LCMS analysis of H9c2 cells. Increased AEA levels were observed in doxorubicin treated samples. *p < 0.05 versus vehicle (n = 3). KO = knockout; other abbreviations as in Figure 1.